COMPANY OVERVIEW

None

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

None

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

Sep 21, 2022

Cellenkos Receives FDA Clearance of Investigational New Drug (IND) Application for CK0803 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) USA - English USA - English USA - English

Jun 16, 2022

Global Cord Blood Corporation Announced Cellenkos Receives FDA Clearance of IND Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis

Jun 14, 2022

Cellenkos Receives FDA Clearance of Investigational New Drug (IND) Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis USA - English English English

Jun 3, 2022

Shareholders Led by Blue Ocean Call Extraordinary General Meeting of Global Cord Blood Corporation Shareholders to Terminate its Proposed Acquisition of Cellenkos, Inc. and Elect New Board

May 13, 2022

Blue Ocean Successfully Applied Injunction to Stop Global Cord Blood from Acquiring Cellenkos Following Cayman Islands Court Ruling

For More Press Releases

---